Key clinical point: Crizanlizumab was effective in sickle cell patients with numerous vaso-occlusive crises, the HbSS genotype, and those who use hydroxyurea.
Major finding: Crizanlizumab eliminated vaso-occlusive crises about seven times more frequently than did placebo in patients with numerous crises (28.0% vs. 4.2%).
Study details: A post hoc analysis of 132 patients from the phase 2 SUSTAIN trial.
Disclosures: The study was sponsored by Novartis. The authors reported financial relationships with Novartis, Bluebird Bio, AstraZeneca, and others.
Kutlar A et al. Am J Hematol. 2018 Oct 8. doi: 10.1002/ajh.25308.
This Week's Must Reads
Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.
QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.
Women less likely to receive industry funds, Weng JK et al. JAMA Netw Open. 2019 Jan. 25. doi: 10.1001/jamanetworkopen.2018.7377.
Must Reads in Anemia
Gene therapy reverses sickle cell phenotype in small study, Esrick EB et al. ASH 2018, Abstract 1023
Sickle cell pain: Opioids appear safe for inpatients, Akinboro OA et al. ASH 2018, Abstract 315
Sickle cell: Daily hydroxyurea safe in African children, Tshilolo L et al. ASH 2018, Abstract 3
Systematic review examines sickle cell trait complications, Naik RP et al. Ann Intern Med. 2018 Oct 30. doi:10.7326/M18-1161
Post hoc analysis of SUSTAIN shows efficacy of crizanlizumab, Kutlar A et al. Am J Hematol. 2018 Oct 8. doi: 10.1002/ajh.25308